Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;19(28):2335-2355.
doi: 10.1080/17435889.2024.2402678. Epub 2024 Sep 24.

Cardiac-targeted and ROS-responsive liposomes containing puerarin for attenuating myocardial ischemia-reperfusion injury

Yan Wang  1   2 , Shengnan Li  1   2 , Wenqun Li  1   2 , Junyong Wu  1   2 , Xiongbin Hu  1   2 , Tiantian Tang  1   2 , Xinyi Liu  1   2
Affiliations

Cardiac-targeted and ROS-responsive liposomes containing puerarin for attenuating myocardial ischemia-reperfusion injury

Yan Wang et al. Nanomedicine (Lond). 2024.

Abstract

Aim: This study aimed to construct an ischemic cardiomyocyte-targeted and ROS-responsive drug release system to reduce myocardial ischemia-reperfusion injury (MI/RI).Methods: We constructed thioketal (TK) and cardiac homing peptide (CHP) dual-modified liposomes loaded with puerarin (PUE@TK/CHP-L), which were expected to deliver drugs precisely into ischemic cardiomyocytes and release drugs in response to the presence of high intracellular ROS levels. The advantages of PUE@TK/CHP-L were assessed by cellular pharmacodynamics, in vivo fluorescence imaging and animal pharmacodynamics.Results: PUE@TK/CHP-L significantly inhibited apoptosis and ferroptosis in H/R-injured cardiomyocytes and also actively targeted ischemic myocardium. Based on these advantages, PUE@TK/CHP-L could significantly enhance the drug's ability to attenuate MI/RI.Conclusion: PUE@TK/CHP-L had potential clinical value in the precise treatment of MI/RI.

Keywords: ROS-responsive; apoptosis; ferroptosis; liposome; myocardial ischemia-reperfusion injury.

Plain language summary

[Box: see text].

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Similar articles

See all similar articles

Cited by

References

    1. Group. WCRCW . World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332–e1345. doi:10.1016/s2214-109x(19)30318-3 - DOI - PMC - PubMed
    1. Ibáñez B, Heusch G, Ovize M, et al. . Evolving therapies for myocardial ischemia/reperfusion injury. J. Am. Coll. Cardiol. 2015;65(14):1454–1471. doi:10.1016/j.jacc.2015.02.032 - DOI - PubMed
    1. Xiang M, Lu Y, Xin L, et al. . Role of Oxidative Stress in Reperfusion following Myocardial Ischemia and Its Treatments. Oxid Med Cell Longev. 2021;2021:6614009. doi:10.1155/2021/6614009 - DOI - PMC - PubMed
    1. Tan Y, Wang X, Gu Y, et al. . Neutrophil and endothelial cell membranes coassembled roflumilast nanoparticles attenuate myocardial ischemia/reperfusion injury. Nanomedicine-Uk. 2024;19(9):779–797. doi:10.2217/nnm-2023-0313 - DOI - PubMed
    1. Zhao T, Wu W, Sui L, et al. . Reactive oxygen species-based nanomaterials for the treatment of myocardial ischemia reperfusion injuries. Bioactive Materials. 2022;7:47–72. doi:10.1016/j.bioactmat.2021.06.006 - DOI - PMC - PubMed

    2. • The innovation of this article was in summarizing the biological properties of ROS and the range of pathological changes triggered by ROS in myocardial ischemia-reperfusion injury.

Publication types

LinkOut - more resources